Shares of Calithera Biosciences Inc (NASDAQ:CALA) traded up 4% during trading on Tuesday . The stock traded as high as $9.15 and last traded at $8.35. 554,600 shares changed hands during trading, a decline of 25% from the average session volume of 743,512 shares. The stock had previously closed at $8.70.

Several analysts recently commented on the stock. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub raised shares of Calithera Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, December 22nd. ValuEngine lowered shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, William Blair assumed coverage on shares of Calithera Biosciences in a research report on Thursday, October 5th. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $15.17.

The firm has a market cap of $305.10, a P/E ratio of -8.69 and a beta of 2.87.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The company had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.02 million. equities analysts anticipate that Calithera Biosciences Inc will post -0.77 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in CALA. Legal & General Group Plc acquired a new position in Calithera Biosciences in the 2nd quarter valued at approximately $120,000. Hillsdale Investment Management Inc. acquired a new position in shares of Calithera Biosciences during the 2nd quarter worth $166,000. Trexquant Investment LP acquired a new position in shares of Calithera Biosciences during the 3rd quarter worth $168,000. GAM Holding AG acquired a new position in shares of Calithera Biosciences during the 2nd quarter worth $206,000. Finally, Voya Investment Management LLC acquired a new position in shares of Calithera Biosciences during the 2nd quarter worth $211,000. Hedge funds and other institutional investors own 72.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Calithera Biosciences (CALA) Trading -4% Higher” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2018/01/04/calithera-biosciences-cala-trading-4-higher.html.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.